4P-Pharma signs a partnership with QuantHealth, a data science start-up taking a unique in-silico approach to clinical trial simulations based on broad real-world data (RWD) and deep molecular drug data. Together, we will conduct in silico clinical trials of our lead drug candidates.
Our partnership will start with the in-silico simulation of the phase II clinical trial of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), which is developed by our spin-off, 4Moving Biotech .
[…] “Thanks to this partnership, we benefit from QuantHealth’s patient-centric models to form virtual cohorts for testing the efficacy of our drugs to optimize the success of in-human clinical trials”, said Revital Rattenbach. “This collaboration is part of our global circular pharmaceutical development approach to accelerate, de-risk and rapidly bring first-in-class and best-in-class therapies to patients.”
“4P-Pharma’s unique translational approach, with a focus on accelerated clinical development, makes them a perfect partner for our clinical trial simulation platform” said Orr Inbar, Co-Founder and CEO of QuantHealth. […]
Read the full press release: PR-Quant_Health_4P-Pharma
Press contact:
Roselina Lam, Business Development and Licensing-in Manager
E-mail: roselina@4p-pharma.com
